<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1870-249X</journal-id>
<journal-title><![CDATA[Journal of the Mexican Chemical Society]]></journal-title>
<abbrev-journal-title><![CDATA[J. Mex. Chem. Soc]]></abbrev-journal-title>
<issn>1870-249X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Química de México A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1870-249X2019000100043</article-id>
<article-id pub-id-type="doi">10.29356/jmcs.v63i1.714</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Identification, synthesis and structure assignment of two impurities of Erlotinib, a drug used for the treatment of some types of cancer]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morales-Vilchis]]></surname>
<given-names><![CDATA[María Guadalupe]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Flores-Sánchez]]></surname>
<given-names><![CDATA[Patricia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Escalante]]></surname>
<given-names><![CDATA[Jaime]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Signa S.A de C.V.  ]]></institution>
<addr-line><![CDATA[Jiutepec Morelos]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Autónoma del Estado de Morelos Centro de Investigaciones Químicas ]]></institution>
<addr-line><![CDATA[Cuernavaca Morelos]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2019</year>
</pub-date>
<volume>63</volume>
<numero>1</numero>
<fpage>43</fpage>
<lpage>49</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1870-249X2019000100043&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1870-249X2019000100043&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1870-249X2019000100043&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: In the synthesis and industrial production of Erlotinib, the formation of organic impurities has been detected, so the identification and control of these is a critical point within the process. Standards for the consumption of pharmaceutical products are well established for active substances. In this sense, the synthesis and unequivocal identification of two impurities of Erlotinib as structural isomers was developed in the present study. The structural characterization of both isomers was confirmed by 1H and 13C-NMR as well as by their X-ray diffraction study.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: Durante la síntesis y producción industrial del Erlotinib, se ha detectado la formación de impurezas orgánicas. La identificación y control de éstas es un punto crítico dentro del proceso. Los estándares de subtancias activas para el consumo de productos farmacéuticos están bien establecidos. En este sentido, en el presente estudio se desarrolló la síntesis e identificación inequívoca de dos impurezas del Erlotinib como isómeros estructurales. La caracterización de ambos isómeros se confirmó por 1H- y 13C-RMN, así como por su estudio de difracción de rayos-X.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Erlotinib]]></kwd>
<kwd lng="en"><![CDATA[Cancer]]></kwd>
<kwd lng="en"><![CDATA[Isomers]]></kwd>
<kwd lng="en"><![CDATA[Impurity]]></kwd>
<kwd lng="es"><![CDATA[Erlotinib]]></kwd>
<kwd lng="es"><![CDATA[Cáncer]]></kwd>
<kwd lng="es"><![CDATA[Isómeros]]></kwd>
<kwd lng="es"><![CDATA[Impurezas]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Hennequin]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Willerval]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
</person-group>
<source><![CDATA[Tetrahedron Lett]]></source>
<year>2009</year>
<numero>50</numero>
<issue>50</issue>
<page-range>1600-2</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chandregowda]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[V. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Reddy]]></surname>
<given-names><![CDATA[G. C.]]></given-names>
</name>
</person-group>
<source><![CDATA[Org. Process Res. Dev]]></source>
<year>2007</year>
<numero>11</numero>
<issue>11</issue>
<page-range>813-6</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Zha]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<source><![CDATA[Res. Chem. Intermed.]]></source>
<year>2013</year>
<numero>39</numero>
<issue>39</issue>
<page-range>2303-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bridjes]]></surname>
<given-names><![CDATA[A. J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Chem. Rev.]]></source>
<year>2001</year>
<numero>101</numero>
<issue>101</issue>
<page-range>2541-72</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bagul]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[G. K.]]></given-names>
</name>
<name>
<surname><![CDATA[Makani]]></surname>
<given-names><![CDATA[V. K. K.]]></given-names>
</name>
<name>
<surname><![CDATA[Tamboli]]></surname>
<given-names><![CDATA[J. R.]]></given-names>
</name>
<name>
<surname><![CDATA[Pal-Bhadra]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Kamal]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Med. Chem. Commun.]]></source>
<year>2017</year>
<numero>8</numero>
<issue>8</issue>
<page-range>1810-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schnur]]></surname>
<given-names><![CDATA[R. C.]]></given-names>
</name>
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[L. D.]]></given-names>
</name>
</person-group>
<collab>PCT Int. Appl.</collab>
<source><![CDATA[]]></source>
<year>1996</year>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="">
<source><![CDATA[Q3A(R2) Impurities in New Drug Substances]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Volk]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Dancsó]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Bakó]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Peltz]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Simig]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Org. Process Res. Dev.]]></source>
<year>2011</year>
<numero>15</numero>
<issue>15</issue>
<page-range>339-42</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="">
<collab>Cambridge Crystallographic Data Center</collab>
<source><![CDATA[CCDC 1535571 for 4 and 1535572 for 5]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crossland]]></surname>
<given-names><![CDATA[R. K.]]></given-names>
</name>
<name>
<surname><![CDATA[Servis]]></surname>
<given-names><![CDATA[K. L.]]></given-names>
</name>
</person-group>
<source><![CDATA[J. Org. Chem.]]></source>
<year>1970</year>
<numero>35</numero>
<issue>35</issue>
<page-range>3195-6</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
